Related Experiment Video

Updated: Jun 1, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Unraveling the molecular mechanism underlying the anticancer activity of CISD2/NAF-1 44-67

Linda Rowland, Itai Alfoni, Ehud Neumann

    Biorxiv : the Preprint Server for Biology
    |January 20, 2025
    PubMed

    Insights

    The novel cancer-targeting peptide NAF-1 44-67 disrupts cancer cell CISD2/NAF-1 protein structure, activating cell death pathways. Dimers of NAF-1 44-67 show enhanced anticancer activity.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Biochemistry

    Background:

    • A novel cancer-targeting peptide, NAF-1 44-67, selectively enters cancer cells and induces apoptosis and ferroptosis.
    • NAF-1 44-67 has demonstrated efficacy in shrinking human breast and ovarian tumors in xenograft models with no observed side effects.

    Purpose of the Study:

    • To elucidate the mechanism by which NAF-1 44-67 exerts its biological activity within cancer cells.
    • To investigate the interaction of NAF-1 44-67 with its target protein, CISD2/NAF-1, and its effect on protein structure.

    Main Methods:

    • Investigated the interaction between NAF-1 44-67 and the CISD2/NAF-1 protein in cancer cells.
    • Compared the anticancer activity of monomeric and dimeric forms of NAF-1 44-67.
    • Evaluated the activity of a related peptide, mitoNEET (mNT 19-42), derived from CISD1.

    Main Results:

    • NAF-1 44-67 targets and disrupts the homodimeric structure of the CISD2/NAF-1 protein in cancer cells.
    • Dimeric forms of NAF-1 44-67 exhibited significantly higher anticancer activity than the monomeric form.
    • The related peptide mitoNEET (mNT 19-42) showed no cancer-killing activity.

    Conclusions:

    • NAF-1 44-67's anticancer mechanism involves targeting and disrupting the CISD2/NAF-1 protein's homodimeric structure.
    • The dimeric form of NAF-1 44-67 holds greater therapeutic potential.
    • These findings advance the understanding of NAF-1 44-67's biological activity and its potential as a novel anticancer therapeutic.

    More Related Videos

    Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

    Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

    Published on: February 9, 2021

    1.5K
    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay11:14

    Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

    Published on: November 10, 2013

    57.5K

    Related Concept Videos

    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    4.6K
    Electron Transport Chain: Complex I and II01:46

    Electron Transport Chain: Complex I and II

    The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
    ROS generation is regulated and maintained at moderate levels necessary...
    10.8K
    M-Cdk Drives Transition Into Mitosis02:15

    M-Cdk Drives Transition Into Mitosis

    Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
    Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
    M cyclin...
    5.5K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.4K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.4K
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.2K